Please login to the form below

Not currently logged in


This page shows the latest sacubitril news and features for those working in and with pharma, biotech and healthcare.

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

drugs. New therapies like Novartis’ heart failure therapy Entresto (sacubitril/valsartan) and cholesterol-lowering PCSK9 inhibitors from Amgen and Sanofi/Regeneron have re-injected growth into the market, although they have

Latest news

More from news
Approximately 5 fully matching, plus 45 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...